(8aR，12aS，13aS)-5,8,8a，9,10,11,12,12a，13,13a-脱氢-3-甲氧基-12-(乙基磺酰基)-6H-异喹啉[2,1-g][1,6]萘啶盐酸盐 | 186002-54-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: (8aR，12aS，13aS)-5,8,8a，9,10,11,12,12a，13,13a-脱氢-3-甲氧基-12-(乙基磺酰基)-6H-异喹啉[2,1-g][1,6]萘啶盐酸盐
• 英文名称: RS 79948-197
• 英文别名: (8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a,13,13a-decahydro-3-methoxy-12-(ethylsulphonyl)-6H-isoquino[2,1-g][1,6]naphthyridine hydrochloride；(8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a,13,13a-dechydro-3-methoxy-12-(ethylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridine hydrochloride；RS79948；[3H]-RS 79948-197；(8aR,12aS,13aS)-3-methoxy-12-ethanesulfonyl-5,6,8a,9,10,11,12,12a,13,13a-decahydro-8H-isoquino[2,1-g][1,6]naphthyridine hydrochloride；RS 79948 hydrochloride；(8aR,12aS,13aS)-12-ethylsulfonyl-3-methoxy-5,6,8,8a,9,10,11,12a,13,13a-decahydroisoquinolino[2,1-g][1,6]naphthyridine;hydrochloride
• CAS: 186002-54-0
• 化学式: C₁₉H₂₈N₂O₃S*ClH
• 分子量: 400.97
• InChiKey: DZTZUOBWDBPPJQ-BQBHMPFISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.85
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  58.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Sulfonyldecahydro-8H-isoquino[2,1-g][1,6]naphthyridines, optical isomers thereof and related compounds
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0288196B1

  公开（公告）日：1993-07-28
• NORADRENERGIC DRUG TREATMENT OF OBSTRUCTIVE SLEEP APNEA
  申请人：Massachusetts Institute of Technology

  公开号：US20180235934A1

  公开（公告）日：2018-08-23

  Aspects of the disclosure relate to methods for treating disorders using agents for promoting hypoglossal motoneuron excitability. In some instances the disorders include obstructive sleep apnea (OSA), cataplexy, attention deficit/hyperactivity disorder (ADHD), attention deficit disorder (ADD) or depression. Related products are also included within the invention.
• US4886798A
  申请人：——

  公开号：US4886798A

  公开（公告）日：1989-12-12
• [EN] NORADRENERGIC DRUG TREATMENT OF OBSTRUCTIVE SLEEP APNEA<br/>[FR] TRAITEMENT PAR MÉDICAMENT NORADRÉNERGIQUE DE L'APNÉE OBSTRUCTIVE DU SOMMEIL
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2017031319A1

  公开（公告）日：2017-02-23

  Aspects of the disclosure relate to methods for treating disorders using agents for promoting hypoglossal motoneuron excitability. In some instances the disorders include obstructive sleep apnea (OSA), cataplexy, attention deficit/hyperactivity disorder (ADHD), attention deficit disorder (ADD) or depression. Related products are also included within the invention.